(MENAFN- EIN Presswire)
SAN FRANCISCO, CA, UNITED STATES, October 7, 2024 /EINPresswire / -- Ainnocence, a next-generation biotech company, is proud to announce the launch of its cutting-edge AAV (Adeno-Associated Virus) design services, powered by the SentinusAI® platform. These services bring a host of advanced capabilities that address critical challenges in gene therapy development:
. Tissue-Specific Targeting: Tailored AAV vectors designed to target distinct tissue types by recognizing specific cell surface receptors, ensuring accurate gene delivery.
. AI-Powered Ultra-High Throughput: Capable of simultaneously optimizing multiple therapeutic targets, significantly speeding up the design process for various diseases.
. No Structural Data Required: Utilizing sequence-based protein language models, overcoming the need for target structure information, which has been a major industry bottleneck. This innovation allows the design of vectors for previously undruggable or flexible targets.
. Rapid Turnaround: Our highly efficient computational platform can deliver optimized AAV vectors in as little as one week, greatly reducing the time from concept to clinic-ready vectors.
Dr. Lurong Pan, CEO of Ainnocence, highlighted the breakthrough nature of these services: "Our AAV design services are a game-changer for gene therapy. We provide a revolutionary approach to tackling complex targets while drastically cutting down design times. This accelerates the development of life-saving therapies for patients who need them the most."
Ainnocence's SentinusAI® platform has already gained industry recognition for AI-driven drug discovery and protein engineering. With the addition of AAV design services, Ainnocence is poised to transform the future of gene therapy and bring innovative solutions to address a wide range of diseases, including rare genetic disorders and cancer.
About Ainnocence
Ainnocence is a biotech leader providing AI-powered drug discovery and therapeutic solutions across multiple industries, including biopharma, chemical, synthetic biology, and renewable energy. Its flagship platform, SentinusAI®, delivers rapid, precise solutions for protein engineering, antibody design, and AAV vector design, revolutionizing drug discovery. Ainnocence is committed to accelerating life-changing medical breakthroughs and fostering a healthier future.
For more information, visit , follow us on LinkedIn , or leave us a message .
Lurong Pan, PhD
Founder & CEO, Ainnocence
+1 205-249-7424
...
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
MENAFN07102024003118003196ID1108754228
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.